Program
zigakibart
Also written as “BION-1301”, “BION-1301 Single Dose” and “BION-1301 Multiple Doses”.
In Novartis's pipeline, Anti-APRIL
. Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma, led by Novartis.
Furthest: phase 3, since May 2, 20236 company-led studies, 3 open or runningNext primary completion: Aug 10, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 63 open or running | phase 3since May 2, 2023 | Nov 3, 2017 | Aug 10, 2027phase 3 · NCT05852938 |
- Named in Novartis’s own pipeline as
FUB523 (zigakibart)
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 3, 2017First study: phase 2 study in Multiple MyelomaFirst studyNCT03340883 · 21 enrolled · United States
- Apr 21, 2019Phase 2 study in Glomerulonephritis, IGANCT03945318 · 103 enrolled · United States, South Korea, United Kingdom
- Aug 17, 2022Phase 1 study in Healthy VolunteerNCT05508204 · 36 enrolled · United States
- May 2, 2023Phase 3 study in Glomerulonephritis, IGANCT05852938 · 383 enrolled · United States, Argentina, Australia and more
- Feb 21, 2025Phase 3 study in Kidney DiseasesNCT06858319 · 220 planned · United States, Argentina, Australia and more
- Aug 21, 2025Phase 2 study in Glomerulonephritis, IGANCT07146906 · 32 planned · United States, Brazil, China and more
Ahead
- Aug 10, 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT05852938
- Jul 12, 2030Primary completion: phase 2 study in Glomerulonephritis, IGANCT07146906
- Jun 25, 2031Primary completion: phase 3 study in Kidney DiseasesNCT06858319
TargetBeta
“Anti-APRIL”the company's pipeline, read by Claude · source
“A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), ”NCIt, by rule
Other programs on TNFSF13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sibeprenlimabrule | Otsuka | phase 3 | 8 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07146906Glomerulonephritis, IGA · United States, Brazil, China and more | 2 | Recruiting | Jul 12, 2030 | 32 |
| NCT06858319Kidney Diseases · United States, Argentina, Australia and more | 3 | Recruiting | Jun 25, 2031 | 220 |
| NCT05852938Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 10, 2027 | 383 |
| NCT05508204Healthy Volunteer · United States | 1 | Completed | Dec 16, 2022 | 36 |
| NCT03945318Glomerulonephritis, IGA · United States, South Korea, United Kingdom | 2 | Completed | Jun 10, 2026 | 103 |
| NCT03340883Multiple Myeloma · United States | 2 | Terminated | Jun 13, 2019 | 21 |
How it is read
Names in the registry
- “BION-1301”, 3 entries
- “zigakibart”, 2 entries
- “BION-1301 Single Dose”, 2 entries
- “BION-1301 Multiple Doses”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 4 studies
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.